Journal Article

DKFZ-2024-00434

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Cytomegalovirus immunoglobulin serology prevalence in patients with newly diagnosed multiple myeloma treated within the GMMG-MM5 phase III trial.

Salwender, H. ; Weinhold, N. ; Benner, A.DKFZ* ; Miah, K.DKFZ* ; Merz, M. ; Haenel, M. ; Jehn, C. ; Mai, E. ; Menis, E. ; Blau, I. ; Scheid, C. ; Hose, D. ; Seckinger, A. ; Luntz, S. ; Besemer, B. ; Munder, M. ; Brossart, P. ; Glass, B. ; Lindemann, H.-W. ; Weisel, K. ; Hanoun, C. ; Schnitzler, P. ; Klemm, S. ; Goldschmidt, H. ; Raab, M. ; Elmaagacli, A.

2024
Taylor & Francis Abingdon, Oxon

This record in other databases:  

Please use a persistent id in citations: doi:10.1080/16078454.2024.2320006

Abstract: The seroprevalence of antibodies against Cytomegalovirus (CMV) is an established poor prognostic factor for patients receiving an allogeneic stem cell transplantation. However, the impact of CMV serology on outcome after autologous stem cell transplantation remains unknown.Here, we analyzed the CMV immunoglobulin (Ig) serology of 446 newly-diagnosed multiple myeloma (MM) patients of the GMMG-MM5 phase III trial with a median follow-up of 58 months.CMV IgG and IgM positivity was seen in 51% and 6% of the patients, respectively. In multivariate analysis CMV IgG and CMV IgM serology show an age-depending effect for PFS. We identified positive CMV IgG/positive CMV IgM serology as an age-depending beneficial factor on PFS.Younger patients with a positive CMV IgG/positive CMV IgM serology experienced a favorable effect on PFS, whereas a positive CMV IgG/positive CMV IgM serology at older age has a disadvantageous effect on PFS.

Keyword(s): Humans (MeSH) ; Cytomegalovirus (MeSH) ; Hematopoietic Stem Cell Transplantation (MeSH) ; Multiple Myeloma: diagnosis (MeSH) ; Multiple Myeloma: therapy (MeSH) ; Prevalence (MeSH) ; Seroepidemiologic Studies (MeSH) ; Transplantation, Autologous (MeSH) ; Immunoglobulins, Intravenous (MeSH) ; Antibodies, Viral (MeSH) ; Immunoglobulin G (MeSH) ; Cytomegalovirus Infections: epidemiology (MeSH) ; Immunoglobulin M (MeSH) ; CMV ; CMV IgM ; CMV-Infection ; GMMG-MM5 Phase III Trial ; age-depending effect ; autologous stem cell transplantation ; maintenance therapy ; multiple myeloma ; cytomegalovirus-specific hyperimmune globulin ; Immunoglobulins, Intravenous ; Antibodies, Viral ; Immunoglobulin G ; Immunoglobulin M

---

Contributing Institute(s):

1. C060 Biostatistik (C060)

Research Program(s):

1. 313 - Krebsrisikofaktoren und Prävention (POF4-313) (POF4-313)

Appears in the scientific report 2024

---

Database coverage:
; ; ; Article Processing Charges ; Clarivate Analytics Master Journal List ; Current Contents - Clinical Medicine ; Current Contents - Clinical Medicine ; DOAJ Seal ; Ebsco Academic Search ; Essential Science Indicators ; Fees ; IF < 5 ; IF < 5 ; JCR ; JCR ; NCBI Molecular Biology Database ; SCOPUS ; SCOPUS ; Science Citation Index Expanded ; Science Citation Index Expanded ; Thomson Reuters Master Journal List ; Web of Science Core Collection ; Web of Science Core Collection

---